Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)

Summary

This is an Italian, multicenter, randomized, open-label phase III trial which will evaluate if Letrozole is superior to standard adjuvant chemotherapy in patients with hormone receptor positive low-grade serous epithelial carcinoma of the ovary (LGSCO). The hypothesis is that letrozole will significantly prolong median progression free survival (PFS) compared with the standard chemotherapy treatment, namely carboplatin AUC 5 and paclitaxel 175 mg/m2.

Timeline

Start

2022-09-22

Primary completion

2029-09-22

Completion

2029-09-22

Publications

• Carbone A, Biagioli E, Salutari V, Lorusso D, Provinciali N, Bocciolone L, Artioli G, Abeni C, Colombo N, De Giorgi U, Guarneri V, Cassani C, Scarfone G, Zavallone L, Donadello N, Donato VD, Giordano M, Scelzi E, Tognon G, Petrella MC, D'Incalci M, Marchini S, Dang HT, Alvisi MF, Corradengo D, Buttiron Webber T, Paleari L, Briata IM, Rutigliani M, Oliva M, Rulli E, DeCensi A. Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial. Tumori. 2026 Feb;112(1):67-74. doi: 10.1177/03008916251395596. Epub 2025 Dec 14.

Drugs

Indications